12.04.2016 • News

Evonik Buys Alkion Biopharma

Germany’s Evonik is strengthening its portfolio of specialty active...
Germany’s Evonik is strengthening its portfolio of specialty active ingredients with an agreement to purchase French start-up company Alkion Biopharma for an undisclosed sum. (Lichtmeister/Shutterstock)

Germany’s Evonik is strengthening its portfolio of specialty active ingredients with an agreement to purchase French start-up company Alkion Biopharma for an undisclosed sum. Headquartered in Evry, Alkion specializes in developing biotechnological active ingredients for the cosmetics industry. The company has developed methods to cultivate plant biomass under laboratory conditions and can obtain extracts with an exceptionally high yield of complex ingredients.

The entire process takes place without altering the plant genome and results, said Franck Michoux, Alkion’s founder and CEO, in unique, innovative cosmetic actives. With this acquisition, Evonik can now offer customers highly effective customized plant-based ingredients and product concepts that set themselves apart from competitors, said Tammo Boinowitz, head of Evonik’s personal care business.

The transaction is due to be completed this month. Alkion was originally founded as a spin-off from Imperial College London in 2011.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read